LX-9211 is under clinical development by Lexicon Pharmaceuticals and currently in Phase II for Diabetic Neuropathic Pain. According to GlobalData, Phase II drugs for Diabetic Neuropathic Pain have an 18% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LX-9211’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LX-9211 overview

LX-9211 (BMS-986176) is under development for the treatment of diabetic peripheral neuropathic pain and postherpetic neuralgia. The drug candidate is an orally-delivered small molecule compound. The drug candidate targets AP2 associated kinase 1 (AAK1).

Lexicon Pharmaceuticals overview

Lexicon Pharmaceuticals (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. Under its Genome5000 program, the company studied nearly 5,000 genes and identified more than 100 protein targets with significant remedial potential in a range of diseases. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin for heart failure and type 1 diabetes. Its clinical and preclinical development programs, LX2761 and LX9211, are meant for the treatment of diabetes and neuropathic pain, respectively. It has business collaborations with several pharmaceutical and biotechnology companies. The company operates an office in New Jersey and has a laboratory in Texas. Lexicon is headquartered at The Woodlands, Texas, the US.

For a complete picture of LX-9211’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.